Which Investors Are Glad To Pay For Mediocre Performance?
David Teten
MARCH 24, 2014
Addepar is precisely trying to collect and convert into software these best practices. (ff The firm hires a lot of PhDs to do research and come out with a wonder drug, and then markets it widely with tons of PR. Teten : I’m not sure I agree, as inevitably some people will look like geniuses in a random distribution of outcomes.
Let's personalize your content